Combinatorial Pharmacogenetic Interactions of Bucindolol and β1, α2C Adrenergic Receptor Polymorphisms

201258 citationsJournal Articlegold Open Access

Authors

Christopher M. O’Connor · Clinical Research Institute

Mona Fiuzat · Clinical Research Institute

Peter E. Carson

Inder S. Anand

Jonathan F. Plehn · National Institutes of Health

Stephen S. Gottlieb · University of Maryland, Baltimore

Marc A. Silver · Advocate Christ Medical Center

JoAnn Lindenfeld

Abstract

On combination, the two sets of AR polymorphisms 1) influenced bucindolol efficacy seemingly unpredictably but consistent with their pharmacologic interactions, and 2) identified subpopulations with enhanced (β(1)389 Arg homozygotes), intermediate (β(1)389 Gly carriers+α(2C)322-325 Wt homozygotes), and no (β(1)389 Gly carriers+α(2C)322-325 Del carriers) efficacy.

Topics & Keywords

Receptor Mechanisms and Signaling Heart Failure Treatment and Management Cardiac electrophysiology and arrhythmias

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: PLoS ONE

Volume 7, Issue 10, pp. e44324-e44324

DOI: 10.1371/journal.pone.0044324

Field-Weighted Citation Impact: 2.68